
Cilta-Cel Yields QOL Benefits and Prolonged Treatment-Free Intervals vs SOC in R/R Myeloma
A single infusion of ciltacabtagene autoleucel (cilta-cel; Carvykti) delayed worsening of disease-related symptoms and functional effects in patients with lenalidomide (Revlimid)–refractory multiple myeloma, who also experienced improved quality of life ( …